Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropyl-β-cyclodextrin

Oral Oncology

Volumn 46, Issue 1, 2010, Pages 42-48

  Berta, Giovanni Nicolao ^a   Salamone, Paolina ^a   Sprio, Andrea Elio ^a   Di Scipio, Federica ^a   Marinos, Lucy Marcela ^a   Sapino, Simona ^a   Carlotti, Maria Eugenia ^a   Cavalli, Roberta ^a   Di Carlo, Francesco ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Chemoprevention; Cyclodextrins; DMBA; Hamster cheek pouch model; Oral cancer; Preneoplastic lesions; Resveratrol

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DIMETHYLBENZ[A]ANTHRACENE; RESVERATROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREAM; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFICACY; HAMSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LEUKOPLAKIA; MOUTH CARCINOMA; MOUTH HYGIENE; NONHUMAN; PRIORITY JOURNAL; SOLUBILIZATION; SQUAMOUS CELL CARCINOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, TOPICAL; ANIMALS; ANTICARCINOGENIC AGENTS; BETA-CYCLODEXTRINS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHEEK; CRICETINAE; DRUG COMBINATIONS; MESOCRICETUS; MOUTH NEOPLASMS; PHARMACEUTICAL VEHICLES; STILBENES;

EID: 72149086142     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.10.007     Document Type: Article

References (44)

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45 4-5 (2009) 309-316
2. Warnakulasuriya S., Johnson N.W., and van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 36 10 (2007) 575-580
3. Splieth C.H., Sumnig W., Bessel F., John U., and Kocher T. Prevalence of oral mucosal lesions in a representative population. Quintessence Int 38 1 (2007) 23-29
4. Lodi G., Sardella A., Bez C., Demarosi F., and Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ 66 8 (2002) 896-902
5. Papadimitrakopoulou V.A., William Jr. W.N., Dannenberg A.J., Lippman S.M., Lee J.J., Ondrey F.G., et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14 7 (2008) 2095-2101
6. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 5297 (1997) 218-220
7. Kundu J.K., and Surh Y.J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 269 2 (2008) 243-261
8. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5 6 (2006) 493-506
9. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarker Prev 16 6 (2007) 1246-1252
10. Yu C., Shin Y.G., Chow A., Li Y., Kosmeder J.W., Lee Y.S., et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 19 12 (2002) 1907-1914
11. Walle T., Hsieh F., DeLegge M.H., Oatis Jr. J.E., and Walle U.K. High absorption but very low bioavailability of oral resveratrol in umans. Drug Metab Dispos 32 12 (2004) 1377-1382
12. Wenzel E., and Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49 5 (2005) 472-481
13. Hung C.F., Lin Y.K., Huang Z.R., and Fang J.Y. Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin. Biol Pharm Bull 31 5 (2008) 955-962
14. Nash R.A. Cyclodextrins. In: Rowe R.C., Ysheskey P., and Owen S.C. (Eds). Handbook of pharmaceutical excipients. 5th ed. (2006), Royal Pharmaceutical Society of Great Britain, London 217-221
15. Del Valle E.M.M. Cyclodextrins and their uses: a review. Process Biochem 39 9 (2004) 1033-1046
16. Hara T., Arima H., Hirayama F., and Uekama K. Enhanced bioavailability of a new thiazolidine derivative FPFS-410, an antidiabetic and lipid-lowering drug, after oral administration of its hydroxypropyl-beta-cyclodextrin complex to bile duct-cannulated rats. J Pharm Sci 95 8 (2006) 1771-1782
17. Carrier R.L., Miller L.A., and Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J Control Release 123 2 (2007) 78-99
18. Uekama K., Hirayama F., and Arima H. Recent aspect of cyclodextrin-based drug delivery system. J Incl Phenom Macrocycl Chem 56 (2006) 3-8
19. Loftsson T., and Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 329 1-2 (2007) 1-11
20. Odukoya O., Schwartz J., Weichselbaum R., and Shklar G. An epidermoid carcinoma cell line derived from hamster DMBA-induced buccal pouch tumors. J Natl Cancer Inst 71 6 (1983) 1253-1264
21. Salley J.J. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res 33 2 (1954) 253-262
22. Vairaktaris E., Spyridonidou S., Papakosta V., Vylliotis A., Lazaris A., Perrea D., et al. The hamster model of sequential oral oncogenesis. Oral Oncol 44 4 (2008) 315-324
23. Mognetti B., Di Carlo F., and Berta G.N. Animal models in oral cancer research. Oral Oncol 42 5 (2006) 448-460
24. Sapino S., Carlotti M.E., Caron G., Ugazio E., and Cavalli R. In silico design, photostability and biological properties of the complex resveratrol/hydroxypropyl-b-cyclodextrin. J Incl Phenom Macrocycl Chem 63 (2009) 171-180
25. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48 17 (1988) 4827-4833
26. Lippman S.M., and Lee J.J. Reducing the "risk" of chemoprevention: defining and targeting high risk - 2005 AACR cancer research and prevention foundation award lecture. Cancer Res 66 6 (2006) 2893-2903
27. Docherty J.J., Smith J.S., Fu M.M., Stoner T., and Booth T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res 61 1 (2004) 19-26
28. Loftsson T., and Masson M. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 225 1-2 (2001) 15-30
29. Gould S., and Scott R.C. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 43 10 (2005) 1451-1459
30. Pirola L., and Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life 60 5 (2008) 323-332
31. Chen Y.K., and Lin L.M. Placental glutathione-S-transferase isoenzyme expression in polycyclic aromatic hydrocarbon-induced hamster buccal pouch mucosa. Oral Oncol 34 3 (1998) 180-185
32. Chen Y.K., and Lin L.M. Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol 36 2 (2000) 221-224
33. Yan M., Schneider J., Gear R., Lu F., LaDow K., Warshawsky D., et al. Expression of angiogenic factors is upregulated in DMBA-induced rat mammary pathologies. Pathobiology 71 5 (2004) 253-260
34. Banerjee S., Bueso-Ramos C., and Aggarwal B.B. Suppression of 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62 17 (2002) 4945-4954
35. Gillison M.L. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 29 8 (2007) 779-792
36. Puga A., Ma C., and Marlowe J.L. The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways. Biochem Pharmacol 77 4 (2009) 713-722
37. Currier N., Solomon S.E., Demicco E.G., Chang D.L., Farago M., Ying H., et al. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 33 6 (2005) 726-737
38. Ciolino H.P., Daschner P.J., and Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58 24 (1998) 5707-5712
39. Casper R.F., Quesne M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol 56 4 (1999) 784-790
40. Szaefer H., Krajka-Kuźniak V., and Baer-Dubowska W. The effect of initiating doses of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene on the expression of PAH activating enzymes and its modulation by plant phenols. Toxicology 251 1-3 (2008) 28-34
41. Koutsas C., Sarigiannis Y., Stavropoulos G., and Liakopoulou-Kyriakides M. Conjugation of resveratrol with RGD and KGD derivatives. Protein Pept Lett 14 10 (2007) 1014-1020
42. Schipper R.G., Silletti E., and Vingerhoeds M.H. Saliva as research material: biochemical, physicochemical and practical aspects. Arch Oral Biol 52 12 (2007) 1114-1135
43. Schwartz J., Shklar G., Reid S., and Trickler D. Prevention of experimental oral cancer by extracts of Spirulina-Dunaliella algae. Nutr Cancer 11 2 (1988) 127-134
44. Chabner B.A., and Roberts Jr. T.G. Chemotherapy and the war on cancer. Nat Rev Cancer 5 1 (2005) 65-72